Despite increasing efforts and support for anti-malarial drug R&D, globally anti-malarial drug discovery and development remains largely uncoordinated and fragmented. The current window of opportunity for large scale funding of R&D into malaria is likely to narrow in the coming decade due to a contraction in available resources caused by the current economic difficulties and new priorities (e.g. climate change). It is, therefore, essential that stakeholders are given well-articulated action plans and priorities to guide judgments on where resources can be best targeted. The CRIMALDDI Consortium (a European Union funded initiative) has been set up to develop, through a process of stakeholder and expert consultations, such priorities and recommendations to address them. It is hoped that the recommendations will help to guide the priorities of the European anti-malarial research as well as the wider global discovery agenda in the coming decade.
CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives / I.C. Boulton, S. Nwaka, I. Bathurst, M. Lanzer, D. Taramelli, H. Vial, C. Doerig, K. Chibale, S.A. Ward. - In: MALARIA JOURNAL. - ISSN 1475-2875. - 9:1(2010 Jul 13).
|Titolo:||CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives|
|Settore Scientifico Disciplinare:||Settore MED/04 - Patologia Generale|
|Data di pubblicazione:||13-lug-2010|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1186/1475-2875-9-202|
|Appare nelle tipologie:||01 - Articolo su periodico|